BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

論壇議程總覽

2024 Innovation Forum Agenda

2024 Innovation Forum Agenda

Date July 24-26, 2024

Venue July 24 TaiNEX2
July 25-26 TaiNEX1

Day 1 - Wednesday, July 24
Day 2 - Thursday, July 25
Day 3 - Friday, July 26

09:00 – 10:30

Session 1 (Plenary) – Global Biotech Development

09:00 – 09:05

Conference Opening

Welcome

Johnsee Lee, Chairman of BIO Asia–Taiwan 2024
Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
John F. Crowley, President and CEO, Biotechnology Innovation Organization (BIO)

09:05 – 09:30

Session Chair

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

【Industry Policy Lecture】

Impact of Key Policy and Regulatory Changing on Biopharma Industry

Cartier Esham, Chief Science Officer, Biotechnology Innovation Organization (BIO)

09:30– 10:00

【Industry Leader Lecture】
Pioneering Company Creation Model and Collaboration opportunities in Asia

André Andonian, Chair of Flagship Asia Pacific, Flagship Pioneering Sabrina Yang, Principal, Flagship Pioneering; Cofounder and Chief Innovation Officer, Empress Therapeutics

10:00 – 10:30

【Tang Prize Lecture】

Exploration of Biological Diversity

Feng Zhang, Tang Prize Lauree; James and Patricia Poitras Professor, MIT, Core Member, Broad Institute of MIT and Harvard

10:30 – 12:15

Session 2 (Plenary) – Global Biotech Development

10:30 – 10:50

Venture Building in Asia within Global Ecosystem

Anis Uzzaman, Founder &CEO, Pegasus Tech Ventures

10:50 – 11:10

Emerging Trends in the Global Health Industry

Zubin J. Daruwalla, M. D., PwC Singapore and Asia Pacific Health Industries Leader

11:10 – 11:30

Global Trends and Future Opportunities in Pharma

Eric Shao, VP, GM of Commercial Sols, GC, IQVIA

11:30 – 11:50

The Big Leap - The Reinvention of Life Science

Speaker from Syneos Health

11:50 – 12:10

AI and Healthtech– the Entangled Couple

Dov Moran, Managing Partner, Grove Ventures

12:10 – 12:15

Closing Remark

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

14:10 – 15:40

Session 4 –ADC drug development and manufacturing trends challenges and solutions

14:10 – 14:15

Opening Remarks

Lee-Cheng Liu, Dr. Sci. Eng., Founder, Chairman and President of EirGenix, Inc.

14:15 – 14:35

Challenges of Regulatory Considerations

Heidi Wang, Chief Executive Officer, OBI Pharma

14:35 – 14:55

Investment Perspectives for ADC Development

Gur Roshwalb, Partner, aMoon

14:55 – 15:15

Technology or solutions of Antibody Drug Conjugate (ADC)

15:10 – 15:40

Panel Discussion

Moderator:
Lee-Cheng Liu, Dr. Sci. Eng., Founder, Chairman and President of EirGenix, Inc.

Panelists:

  • Heidi Wang, Chief Executive Officer, OBI Pharma
  • Gur Roshwalb, Partner, aMoon
  • Edward Hsieh, Vice President of RD, Formosa Laboratories, Inc.
     

16:00 – 17:30

Session 5 – Frontier of Gene and Cell Therapies

16:00 – 16:03

Opening Remarks

16:03 – 16:20

Cell and Gene Therapies Updates

John Tsai, CEO, Forcefield Therapeutics Executive Partner, Syncona

16:20 – 16:40

Integration of CAR-T Value Chain with Enabling Manufacturing Platforms

David Chang, General Manager, Taiwan Bio-Manufacturing Corporation

16:40 – 16:55

Driving the Next Generation of Innovative and Affordable Cell Therapies across Indications.

Alex Huang, VP, Head of Cell Therapy, BeiGene

16:55 – 17:10

Clinical Trials Design and Execution

Speaker from Amarex

17:10 – 17:25

The Perspectives from Investors on Cell and Gene Therapy

Gur Roshwalb, Partner, aMoon

17:25 – 17:30

Closing Remarks

09:00 – 10:30

Session 6 –mRNA and New Therapeutic Modalities

09:00 – 09:05

Opening Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

09:05 – 09:25

New Therapeutic Modalities for Treatment of Human Diseases

Yusuke Nakamura, President, National Institutes of Biomedical Innovation, Health and Nutrition

09:25 – 09:45

Updates for Gene Therapies-An Industry Perspective

John Tsai, CEO, Forcefield Therapeutics, Executive Partner, Syncona

09:45 – 10:05

Initiated from Unthinkable with the Optimization

Eric Huang, Former GM and CSO, Moderna Genomics

10:05 – 10:25

CMC Strategy for mRNA-LNP Vaccines and Therapeutics

Kelvin Chan, Director of Commercial & Business Development, Kudo Biotechnology

10:25 – 10:30

Closing Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

14:10-15:40

Session 9 –Strategic Insights into CMC Program Design: Pioneering Biologics Development Excellence

14:10 – 14:15

Opening Remarks

Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals & Bora Biologics

14:1514:35

Topic (TBC)

Art Chu, CEO, T-E Meds

14:35– 14:55

Topic (TBC)

Paul Song, CSO, GeneQuantum Healthcare

14:55– 15:15

Topic (TBC)

Friedmund Bachmann, VP CMC, OnceOne

15:15- 15:35

Topic (TBC)

Alan Chang, Founder & CEO, Taron Solutions

15:35– 15:40

Closing Remarks

16:00 – 17:30

Session 10 –Translational Medicine, A Journey from Novelty to Commercial Success

16:00-16:05

Opening Remarks

Huey-Kang Sytwu, President, National Health Research Institutes

Moderator:
Hsing-Pon Hsieh, Director, Institute of Biotechnology and Pharmaceutical Research (IBPR), National Health Research Institutes

16:05-16:30

Bozitinib: From Bench to Bedside

Boyu Zhong, Co-founder & President, Tyligand Bioscience Ltd
16:30-16:55

GLP-1: From Anti-Diabetic to Anti-Obesity (TBD)

16:55-17:20

Translation Medicine from CMC perspectives, from Preclinical to Commercial

David Chang, General Manager, Taiwan Bio-Manufacturing Corporation
17:20-17:30

Panel Discussion

Moderator:
Hsing-Pon Hsieh, Director, Institute of Biotechnology and Pharmaceutical Research (IBPR), National Health Research Institutes

Panelists:

  • Boyu Zhong, Co-founder & President, Tyligand Bioscience Ltd
  • David Chang, General Manager, Taiwan Bio-Manufacturing Corporation

09:00 – 10:30

Session 11 – AI for Pharma

09:00 – 09:05

Opening Remarks

09:05 – 09:25

Improving AI Analytical and Predictive Power in Drug Discovery Through Deep Learning Methodologies and Industry Collaboration

Tom Diethe, Executive Director, The Centre for Artificial Intelligence, AstraZeneca
09:25 – 09:45

Unlocking the Potential of AI for High-Throughput Immunotherapy, Drug Discovery Through RNA Splicing

Martin Akerman, Co-Founder & CTO, Envisagenics

09:45 – 10:05

Integrating Artificial Intelligence in the Design and Discovery of Novel Protein Degraders

Shu-Jen Chen, Ph.D., Chief Scientific Officer, AnHorn Medicines

10:05 – 10:25

AI for Pharma: Clinical Perspective

Speaker from Medidata

10:25 – 10:30

Closing Remarks

10:45 – 12:15

Session 12 –Precision Medicine

10:45 – 10:50

Opening Remarks

Kang-Yun Lee, Vice President, Taipei Medical University

10:50 – 11:10

Development of Peptide-Based PPI Inhibitor Targeting the BIG3-PHB2 cancer specific complex for Breast Cancer

Toyomasa Katagiri, Director, National Institutes of Biomedical Innovation, Health and Nutrition

11:10 – 11:30
(Online)

Topic (TBC)

Pankaj J. Pasricha, Mayo Clinic ASSOCIATE MEDICAL DIRECTOR - AZ, BUSINESS DEVELOPMENT

11:30 - 11:50

Development of Precision Respiratory Medicine for chronic inflammation and infection

Kazuhiro Ito, Professor, Imperial College London

11:50 – 12:15

Panel Discussion

Moderator:

  • Teh-Ying Chou, Vice Superintendent for Research and Development, Director, Precision Medicine Research Center, Taipei Medical University Hospital

Panelist:

  • Pankaj J. Pasricha, Mayo Clinic Associate Medical Director - AZ, Business Development
  • Kazuhiro Ito, Professor, Imperial College London
  • Sungmei Hsiung, Partner and Law & Tech Innovation Service Leader, Deloitte Legal

12:25 – 13:55

Session 13 –Shaping the Future of Digital Health

12:25 - 12:35

Opening Remarks

Representative from MOEA, Taiwan
Eric Y. Chuang, General Director, Biomedical Technology and Device Research
Laboratories (BDL), ITRI

12:35 - 13:15

Digital Health Trends and Global Business Strategies

  • Nipun Jain, Head of Innovation Hubs & Partnerships for International, AstraZeneca
  • Jason Ma, Engineering Director, Technical Site Lead, Google Taiwan
13:15 - 13:55

Panel Discussion: Bridging the Gap – Expand the Cross-Disciplinary Digital Health Community

Moderator:
Eric Y. Chuang, General Director, BDL, ITRI

Panelists:

  • Abovementioned 2 Speakers
  • Kai-Cheng Hsu, Chief Medical Officer and Division Director, Biomedical Big Data & Artificial Intelligence Technology Division, BDL, ITRI
  • Representative from venture capital